Status:
UNKNOWN
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Lead Sponsor:
Yunfei Yuan
Conditions:
Intrahepatic Cholangiocarcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%. S...
Eligibility Criteria
Inclusion
- ICC diagnosed by imaging examination (CT or MRI) and pathology;
- ICC patient without any previous tumor treatment
- The tumor was assessed as unresectable by two liver surgeons. Any of the following conditions: (1) Residual liver volume less than 30-40%; (2) Not possible for R0 radical resection; (3) Tumor invades the portal vein, hepatic artery and bile duct, and the normal residual liver cannot be guaranteed blood supply and bile drainage; the tumor involves the hepatic veins and cannot preserve at least one vein.
- At least one assessable intrahepatic lesion;
- ECOG PS score 0-1;
- Child-Pugh class A;
- Life expectancy is at least 3 months;
- Age between 18 and 75 years old;
- Baseline laboratory tests meet the following criteria:
- Neutrophils ≥1.5×10\^9/L White blood cells ≥3.0×10\^9/L Platelets ≥75×10\^9/L Hemoglobin ≥80g/L Serum ALT, AST ≤ 3 x upper limit of normal (ULN) Serum creatinine ≤ 1.5 x ULN INR \< 1.5, or prothrombin time \< ULN+4 seconds Albumin ≥30g/L Total bilirubin ≤ 3 x upper limit of normal (ULN)
Exclusion
- Distant metastasis;
- Refused to receive PD-1 inhibitor and apatinib treatment;
- Any of the following conditions within the first 12 months of the study: myocardial infarction, severe/unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), Pulmonary embolism; ongoing: arrhythmia grade ≥2 according to NCI-CTCAE criteria, QTc prolongation (\>450 ms in men, \>470 ms in women);
- Renal insufficiency requires peritoneal dialysis or hemodialysis;
- Serious dysfunction of other important organs;
- A second primary malignant tumor was diagnosed in the past;
- Known or new evidence of brain or leptomeningeal lesions;
- Hemophilia or bleeding tendency, who are taking anticoagulation therapy such as coumarin derivatives in therapeutic doses;
- Pregnant or lactating women, all female patients of childbearing potential must undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative;
- History of previous organ transplantation;
- Known HIV infection;
- Allergy to chemotherapy drugs;
- Patients with other serious acute or chronic physical or psychiatric diseases or abnormal laboratory tests that may increase the risk associated with participating in the study, or may interfere with the interpretation of the study results or the investigators consider unsuitable for enrollment.
Key Trial Info
Start Date :
July 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT05290116
Start Date
July 21 2022
End Date
September 1 2023
Last Update
August 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060